Long term efficacy: Idebenone reduces the rate of both inspiratory and expiratory functional loss in Duchenne muscular dystrophy (DMD)

O. Mayer (Philadelphia, United States of America), M. Leinonen (Pratteln, Switzerland), S. Hasham (Pratteln, Switzerland), G. Buyse On Behalf Of The Syros Investigators (Leuven, Belgium)

Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives
Session: Rare and ultra-rare diseases and the lungs: updates and new perspectives
Session type: Oral Presentation
Number: 5331
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Mayer (Philadelphia, United States of America), M. Leinonen (Pratteln, Switzerland), S. Hasham (Pratteln, Switzerland), G. Buyse On Behalf Of The Syros Investigators (Leuven, Belgium). Long term efficacy: Idebenone reduces the rate of both inspiratory and expiratory functional loss in Duchenne muscular dystrophy (DMD). 5331

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: